The Healthcare Technology Report names Rohan F. Hastie a Top 50 Healthcare Technology CEO of 2021
President and Chief Executive Officer since 2018, Rohan Hastie has helped usher North Carolina-based firm Metabolon into a new era of success in the fields of precision medicine and clinical metabolomics.
MORRISVILLE, N.C. – May 17, 2021 – Rohan F. Hastie, Ph.D., President & CEO, Metabolon, Inc. has been recognized as one of the top 50 healthcare technology CEOs for 2021 by The Healthcare Technology Report. The ranking includes leaders who are driving cutting-edge technologies and unique opportunities for transformative growth within their areas of expertise.
Dr. Hastie has been at the helm of Metabolon since 2018, when initiated the company’s efforts to dramatically expand awareness and application of metabolomics in the biopharma market, setting a vision of enlightening life and enabling a healthier world. Under Dr. Hastie’s leadership, the company as expanded its commercial client base and secured significant investor funding to fuel new R&D programs in machine learning, novel biomarker discovery and an expanded precision medicine platform. Metabolon continues to demonstrate to researchers how metabolomics can be performed at scale with precision and quality assurance to support biopharma throughout the drug development continuum.
“At Metabolon, we are leveraging all of our talents and capabilities to become a diversified leader in healthcare and enable our clients to make important scientific breakthroughs,” says Hastie. “Metabolomics is a valuable tool that supports researchers in understanding internal and external factors of disease to improve the health and well-being of people.”
Metabolomics, the large-scale study of all small molecules in a biological system, is the only ‘omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond just the genetic variation of individuals, by capturing the combined impact of genetic as well as external factors, such as the effect of drugs, diet, lifestyle and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers that can enable understanding of a drug’s mechanism of action (MOA), pharmacodynamics, safety profile, and individual response to therapy.
Metabolon, Inc., is the global leader in metabolomics, with a mission to deliver metabolomics data and insights that expand and accelerate the impact of life sciences research in all its applications. Over 20 years, 10,000+ projects, 2,000+ publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific technology and bioinformatics techniques. Our Precision Metabolomics™ Platform has enabled the development of the world’s largest proprietary metabolomics reference library. Our industry-leading data and translational science experts help our clients address some of the most challenging and pressing questions in the life sciences, accelerating research, and development success. The company offers scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.
Elizabeth Romero, Manager, Marketing Communications, Metabolon, Inc., Mobile: 984-243-1413, email@example.com